U.S. drug maker Moderna is eyeing a possible investment in manufacturing facilities in Germany, and its top executive says plants that German competitor BioNTech is planning to shut down could be an attractive option.
CEO Stephane Bancel shared the company’s interest with the German business newspaper Handelsblatt on Wednesday, June 17, indicating that existing infrastructure could be more appealing than starting a new construction project.
“If we were to find the right partnership with the German government, these facilities would be an interesting option — compared with building a new one,” Bancel told the publication.
The comments signal Moderna’s ambition to expand its European manufacturing footprint by potentially stepping in where its rival plans to step back.
